• 1
    Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Raebel MA, Roblin D, Smith DH, Yood MU, Morse AN, Platt R. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191: 398407.
  • 2
    Bakker MK, Jentink J, Vroom F, Van Den Berg PB, De Walle HE, De Jong-Van Den Berg LT. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006; 113: 55968.
  • 3
    Engeland A, Bramness JG, Daltveit AK, Ronning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006. Br J Clin Pharmacol 2008; 65: 65360.
  • 4
    Gagne JJ, Maio V, Berghella V, Louis DZ, Gonnella JS. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 2008; 64: 112532.
  • 5
    Olesen C, Steffensen FH, Nielsen GL, de Jong-van den Berg, Olsen J, Sorensen HT. Drug use in first pregnancy and lactation: a population-based survey among Danish women. The EUROMAP group. Eur J Clin Pharmacol 1999; 55: 13944.
  • 6
    Graves CR. Pneumonia in pregnancy. Clin Obstet Gynecol 2010; 53: 32936.
  • 7
    Laibl V, Sheffield J. The management of respiratory infections during pregnancy. Immunol Allergy Clin North Am 2006; 26: 15572. viii.
  • 8
    Rours GI, Duijts L, Moll HA, Arends LR, de GR, Jaddoe VW, Hofman A, Steegers EA, Mackenbach JP, Ott A, Willemse HF, van der Zwaan EA, Verkooijen RP, Verbrugh HA. Chlamydia trachomatis infection during pregnancy associated with preterm delivery: a population-based prospective cohort study. Eur J Epidemiol 2011; 26: 493502.
  • 9
    Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. Atlanta, GA: Centers for Disease Control and Prevention, 2011. Available at (last accessed 30 April 2012).
  • 10
    World Health Organization. Sexually Transmitted and Other Reproductive Tract Infections. A Guide to Essential Practice. Geneva: World Health Organization, 2005.
  • 11
    Briggs GG, Freeman RK, Yaffe SJ, eds. Drugs in Pregnancy and Lactation. A Reference Guide to Fetal and Neonatal Risk, 7th Edition. Baltimore, MD: Lippincott Williams & Wilkins, 2005; 58890.
  • 12
    Kallen BA, Otterblad OP, Danielsson BR. Is erythromycin therapy teratogenic in humans? Reprod Toxicol 2005; 20: 20914.
  • 13
    Källen KBM. Maternal drug use in early pregnancy and risk of cardiovascular defect in infant – A follow-up study. Reprod Toxicol 2008; 26: 645. (Abstract presented at the 36th Annual Conference of the European Teratology Society, Sept 21-24 2008; Edinburgh, Scotland).
  • 14
    Källén BA. Drugs during Pregnancy. New York: Nova Science Publishers Inc, 2009.
  • 15
    Norwegian Medicines Agency. [Drugs during pregnancy][Internet]. 2007. Norwegian. Available at (last accessed 30 April 2012).
  • 16
    The Swedish Medical Products Agency. [Erythromycin should be avoided in early pregnancy][Internet]. 2006. Swedish. Available at–2005/Erytromycin-bor-undvikas-under-tidig-graviditet/ (last accessed 30 April 2012).
  • 17
    Therapeutic Goods Administration.Prescribing medicines in pregnancy database [Internet]. 2012. Department of Health and Ageing, Australian Government. Available at (last accessed 30 April 2012).
  • 18
    Drugs Information Online. Eythromycin Tablets [Internet]. 2012. Available at (last accessed 30 April 2012).
  • 19
    World Health Organization. Guidelines for the Management of Sexually Transmitted Infections. Geneva: World Health Organization, 2003.
  • 20
    Jones D. Use of erythromycin in pregnancy. [Internet]. UK Teratology Information Service. 2009. Available at (last accessed 30 April 2012).
  • 21
    Eurocat. Eurocat Special Report. Congenital heart defects in Europe 2000-2005. University of Ulster: eurocat central registry. 2009. Available at (last accessed 30 April 2012).
  • 22
    Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 2007; 115: 16372.
  • 23
    Brennan P, Young ID. Congenital heart malformations: aetiology and associations. Semin Neonatol 2001; 6: 1725.
  • 24
    Pierpont ME, Basson CT, Benson DW Jr, Gelb BD, Giglia TM, Goldmuntz E, McGee G, Sable CA, Srivastava D, Webb CL. Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 2007; 115: 301538.
  • 25
    Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, Elixson M, Warnes CA, Webb CL. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 2007; 115: 29953014.
  • 26
    Sadler TW. Langman's Medical Embryology, 6th Edition. Baltimore, MD: Williams & Wilkins, 1990.
  • 27
    WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2011. Oslo: World Health Organization, 2010.
  • 28
    Bar-Oz B, Diav-Citrin O, Shechtman S, Tellem R, Arnon J, Francetic I, Berkovitch M, Ornoy A. Pregnancy outcome after gestational exposure to the new macrolides: a prospective multi-center observational study. Eur J Obstet Gynecol Reprod Biol 2008; 141: 314.
  • 29
    Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: national Birth Defects Prevention Study. Arch Pediatr Adolesc Med 2009; 163: 97885.
  • 30
    Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod Toxicol 1999; 13: 5316.
  • 31
    Drinkard CR, Shatin D, Clouse J. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. Pharmacoepidemiol Drug Saf 2000; 9: 54956.
  • 32
    Einarson A, Phillips E, Mawji F, D’Alimonte D, Schick B, Addis A, Mastroiacova P, Mazzone T, Matsui D, Koren G. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 1998; 15: 5235.
  • 33
    Louik C, Werler MM, Mitchell AA. Erythromycin use during pregnancy in relation to pyloric stenosis. Am J Obstet Gynecol 2002; 186: 28890.
  • 34
    Cubeddu LX. Iatrogenic QT abnormalities and fatal arrhythmias: mechanisms and clinical significance. Curr Cardiol Rev 2009; 5: 16676.
  • 35
    Simko J, Csilek A, Karaszi J, Lorincz I. Proarrhythmic potential of antimicrobial agents. Infection 2008; 36: 194206.
  • 36
    Stanat SJ, Carlton CG, Crumb WJ Jr, Agrawal KC, Clarkson CW. Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem 2003; 254: 17.
  • 37
    Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: points of interest. Clin Infect Dis 2006; 43: 160311.
  • 38
    Danielsson BR, Skold AC, Azarbayjani F. Class III antiarrhythmics and phenytoin: teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage. Curr Pharm Des 2001; 7: 787802.
  • 39
    Shepard TH. ‘Proof’ of human teratogenicity. Teratology 1994; 50: 978.
  • 40
    Kubon C, Sivertsen A, Vindenes HA, Abyholm F, Wilcox A, Lie RT. Completeness of registration of oral clefts in a medical birth registry: a population-based study. Acta Obstet Gynecol Scand 2007; 86: 14537.
  • 41
    Melve KK, Lie RT, Skjaerven R, Van Der Hagen CB, Gradek GA, Jonsrud C, Braathen GJ, Irgens LM. Registration of Down syndrome in the medical birth registry of Norway: validity and time trends. Acta Obstet Gynecol Scand 2008; 87: 82430.
  • 42
    Källén BA. Methodological issues in the epidemiological study of the teratogenicity of drugs. Congenit Anom 2005; 45: 4451.
  • 43
    Gjelstad S, Straand J, Dalen I, Fetveit A, Strøm H, Lindbæk M. Do general practicioners' consultation rates influence their prescribing patterns for acute respiratory tract infections? J Antimicrob Chemother 2011; 66: 242533.
  • 44
    Engeland A, Bjorge T, Daltveit AK, Vollset SE, Furu K. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. Acta Obstet Gynecol Scand 2009; 88: 10839.